Thrombophilia, combined oral contraceptives and hormone replacement

被引：0

作者：

Pollak, M. ^{[1
]}

Nagler, M. ^{[2
,3
]}

机构：

[1] Inselspital Univ Spital, Univ Klin Hamatol & Hamatol Zent Lab, Bern, Switzerland

[2] Inselspital Univ Spital, Univ Inst Klin Chem, Freiburgerstr, CH-3010 Bern, Switzerland

[3] Univ Bern, Freiburgerstr, CH-3010 Bern, Switzerland

来源：

GYNAKOLOGISCHE ENDOKRINOLOGIE | 2019年 / 17卷 / 03期

关键词：

Venous thromboembolism/epidemiology; Venous thromboembolism/prevention and control; Contraceptives; oral; combined/adverse effects; Estrogen replacement therapy/adverse effects; Thrombophilia/diagnosis; DEEP-VEIN THROMBOSIS; ED AMERICAN-COLLEGE; VENOUS THROMBOEMBOLISM; ANTITHROMBOTIC THERAPY; PULMONARY-EMBOLISM; RISK-ASSESSMENT; 1ST EPISODE; PROTEIN-C; DEFICIENCY; RECURRENCE;

D O I：

10.1007/s10304-019-0262-y

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Combined oral contraceptives (COC) and hormone replacement treatment are used by millions of women worldwide due to the reliable contraception and other health benefits they offer. Although side effects are few, the treatment puts patients at risk for venous and atrial thromboembolism. The following article describes common thrombophilic situations and risk factors for deep vein thrombosis and pulmonary embolism. The thromboembolic risk of patients treated with different types of estrogen-containing drugs is summarized and related risk factors discussed. Guidance for use in clinical practice is also provided.

引用

页码：139 / 147

页数：9

共 29 条

[1] Thrombophilia testing: Update, guidelines in the greyzones [J].

Angelillo-Scherrer, Anne ;

Nagler, Michael .

THERAPEUTISCHE UMSCHAU, 2016, 73 (10) :626-634

[2] Risk Assessment Scores for Cancer-Associated Venous Thromboembolic Disease [J].

Angelini, Dana ;

Khorana, Alok A. .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2017, 43 (05) :469-478

[3] FSRH Guideline (January 2019) Combined Hormonal Contraception [J].

不详 .

BMJ SEXUAL & REPRODUCTIVE HEALTH, 2019, 45 :I-+

[4] VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].

Bates, Shannon M. ;

Greer, Ian A. ;

Middeldorp, Saskia ;

Veenstra, David L. ;

Prabulos, Anne-Marie ;

Vandvik, Per Olav .

CHEST, 2012, 141 (02) :E691S-E736S

[5] Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia [J].

Bushman, JE ;

Palmieri, D ;

Whinna, HC ;

Church, FC .

LEUKEMIA RESEARCH, 2000, 24 (07) :559-565

[6] RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PARTIAL DEFICIENCY OF PROTEIN-S [J].

COMP, PC ;

ESMON, CT .

NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (24) :1525-1528

[7] INHERITED RESISTANCE TO ACTIVATED PROTEIN-C IS CORRECTED BY ANTICOAGULANT COFACTOR ACTIVITY FOUND TO BE A PROPERTY OF FACTOR-V [J].

DAHLBACK, B ;

HILDEBRAND, B .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (04) :1396-1400

[8] INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA [J].

EGEBERG, O .

THROMBOSIS ET DIATHESIS HAEMORRHAGICA, 1965, 13 (3-4) :516-&

[9] Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism [J].

Eichinger, S ;

Weltermann, A ;

Minar, E ;

Stain, M ;

Schönauer, V ;

Schneider, B ;

Kyrle, PA .

ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (01) :92-96

[10] D-dimer levels and risk of recurrent venous thromboembolism [J].

Eichinger, S ;

Minar, E ;

Bialonczyk, C ;

Hirschl, M ;

Quehenberger, P ;

Schneider, B ;

Weltermann, A ;

Wagner, O ;

Kyrle, PA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (08) :1071-1074

← 1 2 3 →